LGALS3 and metabolic dysfunction-associated steatotic liver disease: Recently, various natural products and drugs have been considered for potential therapeutic agents targeting KCs or macrophages to treat NAFLD, including RFAs, Fenretinide, Toyocamycin, Losartan, EGCG, CCR2/CCR5 antagonist, and Gal-3 inhibitor.